ExodusPoint Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

ExodusPoint Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,410	Closed	-$519K	–	2220
2023 Q2	$519K	Sell	18,410 -56,182	-75%	-$1.35M	﹤0.01%	1341
2023 Q1	$1.28M	Sell	74,592 -11,053	-13%	-$224K	0.01%	1053
2022 Q4	$1.73M	Sell	85,645 -72,324	-46%	-$1.56M	0.03%	712
2022 Q3	$3.42M	Buy	+157,969	New	+$4.32M	0.04%	542
2021 Q3	–	Sell	-5,300	Closed	-$282K	–	2730
2021 Q2	$282K	Buy	+5,300	New	+$284K	﹤0.01%	1779

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

ExodusPoint Capital Management's ZNTL Position: Q3 2023 in Review

ExodusPoint Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2023, closing a stake of 18,410 shares — an estimated $519K sold.

ExodusPoint Capital Management first reported a position in ZNTL in Q2 2021 and held it in 5 quarters. The position peaked at $3.42M in Q3 2022. 137 funds tracked by Wall St. Rank hold ZNTL as of Q3 2023.

ExodusPoint Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 18,410 Zentalis Pharmaceuticals shares in Q3 2023, an estimated $519K.
ExodusPoint Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 5 quarters.
ExodusPoint Capital Management's Zentalis Pharmaceuticals position peaked at $3.42M in Q3 2022.
137 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2023.

Based on ExodusPoint Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.